IP Library › Patent Application 13252982
Patent Application
App. No. 13/252,982

BELOXEPIN AND ANALOGS FOR THE TREATMENT OF PAIN

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/252,982
Abstract

This present disclosure provides methods of treating pain with beloxepin and/or beloxepin analogs.

Claims (22)

1 . A method of treating pain in a mammal, comprising administering to a mammal suffering from pain an amount of beloxepin, or a salt thereof, effective to treat the pain.

2 . The method of claim 1 in which the beloxepin is administered parenterally.

3 . The method of claim 1 in which the beloxepin is administered orally.

4 . The method of claim 1 in which the pain is acute or chronic pain of nociceptive origin.

5 . The method of claim 4 in which the pain is inflammatory pain.

6 . The method of claim 4 in which the pain is cancer pain.

7 . The method of claim 1 in which the pain is chronic pain of non-nociceptive origin.

8 . The method of claim 7 in which the pain is neuropathic pain.

9 . The method of claim 1 in which the pain is visceral pain.

10 . The method of any one of claims 1 - 9 in which the mammal is a human.

11 . A method of treating pain in a mammal, comprising administering to a mammal suffering from pain an amount of beloxepin and/or a beloxepin analog, or a salt thereof, effective to treat the pain.

12 . The method of claim 11 in which the pain is acute or chronic pain of nociceptive origin.

13 . The method of claim 12 in which the pain is inflammatory pain.

14 . The method of claim 12 in which the pain is cancer pain.

15 . The method of claim 11 in which the pain is chronic pain of non-nociceptive origin.

16 . The method of claim 15 in which the pain is neuropathic pain.

17 . The method of claim 11 in which the pain is visceral pain.

18 . The method of any one of claims 11 - 17 in which the beloxepin, beloxepin analog and/or a salt thereof, is administered to the mammal in the form of a composition.

19 . The method of claim 18 in which the beloxepin and/or beloxepin analog is included in the composition as a salt.

20 . The method of claim 18 in which the mammal is a human.

21 . The method of claim 18 in which the composition is formulated for oral administration

22 . The method of claim 21 in which the mammal is a human.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2015
From: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
To: CALIXA THERAPEUTICS, INC.; ADOLOR CORPORATION; CUBIST PHARMACEUTICALS, INC.
Reel/Frame 036180/0070 →
SECURITY AGREEMENT Recorded Nov 20, 2012
From: CUBIST PHARMACEUTICALS, INC.; ADOLOR CORPORATION; CALIXA THERAPEUTICS, INC.; CUBIST PHARMACEUTICALS HOLDINGS, INC.; CUBIST PHARMACEUTICALS U.S.
To: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
Reel/Frame 029339/0669 →